CN102100679A - Carprofen matrix tablets - Google Patents
Carprofen matrix tablets Download PDFInfo
- Publication number
- CN102100679A CN102100679A CN 200910255664 CN200910255664A CN102100679A CN 102100679 A CN102100679 A CN 102100679A CN 200910255664 CN200910255664 CN 200910255664 CN 200910255664 A CN200910255664 A CN 200910255664A CN 102100679 A CN102100679 A CN 102100679A
- Authority
- CN
- China
- Prior art keywords
- carprofen
- hydroxypropyl methylcellulose
- matrix tablet
- lubricant
- filler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to carprofen matrix tablets. The carprofen matrix tablets consist of carprofen serving as an active ingredient, hydroxypropyl methyl cellulose (methocel E4M) serving as a macromolecular material, filling agent and lubricating agent. The prepared carprofen matrix tablets have good medicament slow-release effect, and have long acting time and low adverse response compared with common tablets. The preparation process is simple, the cost is low, the product quality is stable, and the preparation process is suitable for industrialized production.
Description
Technical field
The present invention relates to a kind of carprofen matrix tablet that is used for the treatment of arthritis, arthritis pain and operation pain such as Canis familiaris L., cat.
Background technology
Carprofen is that the efficient animal of developing the seventies in 20th century is used anti-inflammatory agent, belongs to propionic non-steroid antiphlogistic, its chemical name: 6-chloro-Alpha-Methyl-9H-carbazole-2-acetic acid. molecular formula: C15H12ClNO2, and molecular weight: 273.72, chemical structural formula:
Carprofen has stronger anti-inflammatory and antalgic anti rheumatism action, and side effect is little.Obtained extensive use in the U.S., Canada and European a plurality of country.At U.S.'s carprofen is the efficient COX-2 selectivity anti-inflammatory agent that is used for Canis familiaris L. by Food and Drug Administration, veterinary drug committee (FDA/CVM) approval.The carprofen characteristics are that analgesic activity is strong, and clinical rheumatoid arthritis, the osteoarthrisis deformans knee of can be used for also can be used for pain, inflammation and limping that osteoarthritis causes, perhaps because wound, Soft Tissue Treatment and postoperative pain.
Behind the oral carprofen of animal such as dog, cat, absorb rapidly, and with higher CONCENTRATION DISTRIBUTION in liver, kidney, blood plasma, its a small amount of metabolite comprises the glucuronic acid and the oxide ester conjugate of direct conjugate of carprofen and original shape thing, mainly discharges through urine.It is original shape drug level 1-2h peaking after administration in vivo, and biological half-life is shorter, needs administration frequent, and long term administration easily produces untoward reaction; In order to reduce administration number of times, we have developed the carprofen matrix tablet, and this matrix tablet is framework material with the hydroxypropyl methylcellulose, take the back tablet surface and form the stiff gel barrier of one deck, the release of blocking medicine prolongs tablet in the gastrointestinal holdup time, makes medicine reach the effect of controlled release.
Summary of the invention
The present invention provides a kind of carprofen matrix tablet that is used for the treatment of arthritis, arthritis pain and operation pain such as Canis familiaris L., cat first.
An object of the present invention is to provide a kind of carprofen matrix tablet, active component is a carprofen.
Another object of the present invention provides a kind of preparation method of described carprofen matrix tablet.
A kind of carprofen matrix tablet, it is composed as follows, the weight share meter:
Carprofen: 50 parts, hydroxypropyl methylcellulose: 40-120 part, filler: 0-60 part, lubricant: 5-15 part.
Contain carprofen 25mg-75mg in the described carprofen matrix tablet.
Described hydroxypropyl methylcellulose is one or more among hydroxypropyl methylcellulose E4M, hydroxypropyl methylcellulose F4M, hydroxypropyl methylcellulose K4M, hydroxypropyl methylcellulose K15M, the hydroxypropyl methylcellulose K100M.
Described filler is one or more in starch, microcrystalline Cellulose, lactose, amylum pregelatinisatum, Icing Sugar, inorganic salt, the mannitol.
Described lubricant is one or more in magnesium stearate, micropowder silica gel (Aerosil 200 and Aerosil 300), Pulvis Talci, the Polyethylene Glycol.
Concrete preparation method of the present invention is as follows:
Principal agent and adjuvant hydroxypropyl methylcellulose, filler, lubricant are crossed 100 mesh sieves, take by weighing recipe quantity principal agent carprofen and filler and minor amounts of lubricants, mix homogeneously adds adhesive system soft material, the granulation of sieving, drying, granulate adds the lubricant of surplus, mixing is pressed into controlled release tablet, promptly.
In the polyvidone aqueous solution that described adhesive is water, percent by volume are the ethanol water of 5%-30%, starch slurry that mass percent is 1%-15%, mass percentage concentration is 1%-15% a cellulose derivative aqueous solution, mass percentage concentration is 1%-15%, the aqueous gelatin solution that mass percentage concentration is 1%-15%, the Polyethylene Glycol aqueous solution that mass percentage concentration is 1%-15% any.
Carprofen matrix tablet of the present invention selects for use hydroxypropyl methylcellulose and microcrystalline Cellulose mixed matrix material to make the carprofen matrix tablet, infers that through results of stability the controlled release tablet that contains carprofen 50mg is preserved 3 years steady qualities under 25 ℃ of conditions.Show that constant product quality is good.
Carprofen matrix tablet of the present invention is used for the treatment of arthritis, arthritis pain and operation pain such as Canis familiaris L., cat.Preparation technology of the present invention is simple, and cost is low, is suitable for suitability for industrialized production.
The specific embodiment
The following embodiment that provides just in order to help to understand the present invention, rather than constitutes protection domain of the present invention is played restrictive effect, under design prerequisite of the present invention the present invention is simply changed, and all belongs to the scope of protection of present invention.
Embodiment 1:
Prescription is formed:
Carprofen 50mg
Hydroxypropyl methylcellulose 80mg
Microcrystalline Cellulose 50mg
Magnesium stearate 7.5mg
Polyvinylpyrrolidone 7.5mg
Every total amount 200mg
Preparation method: carprofen and adjuvant hydroxypropyl methylcellulose, microcrystalline Cellulose, magnesium stearate are crossed 100 mesh sieves, take by weighing recipe quantity principal agent carprofen and adjuvant hydroxypropyl methylcellulose, microcrystalline Cellulose and a small amount of magnesium stearate, with 10% polyvinylpyrrolidone aqueous solution is that adhesive is granulated, dry, granulate, the magnesium stearate of adding surplus, mixing, be pressed into controlled release tablet, promptly.
Embodiment 2:
Prescription is formed:
Carprofen 50mg
Hydroxypropyl methylcellulose 80mg
Microcrystalline Cellulose 50mg
Magnesium stearate 4mg
Micropowder silica gel (Aerosil 200) 3.5mg
Polyvinylpyrrolidone 7.5mg
Every total amount 200mg
Preparation method: carprofen and adjuvant hydroxypropyl methylcellulose, microcrystalline Cellulose, magnesium stearate are crossed 100 mesh sieves, take by weighing recipe quantity principal agent carprofen and adjuvant hydroxypropyl methylcellulose, microcrystalline Cellulose and a small amount of magnesium stearate and micropowder silica gel, with 10% polyvinylpyrrolidone aqueous solution is that adhesive is granulated, dry, granulate, the magnesium stearate and the micropowder silica gel of adding surplus, mixing, be pressed into controlled release tablet, promptly.
Claims (7)
1. carprofen matrix tablet is characterized in that following composition of containing of it, the weight share meter:
Carprofen: 50 parts
Hydroxypropyl methylcellulose: 40-120 part
Filler: 0-60 part
Lubricant: 5-15 part
2. according to the described carprofen matrix tablet of claim 1, it is characterized in that containing carprofen 25mg-75mg.
3. according to the described carprofen matrix tablet of claim 1, it is characterized in that described hydroxypropyl methylcellulose is one or more among hydroxypropyl methylcellulose E4M, hydroxypropyl methylcellulose F4M, hydroxypropyl methylcellulose K4M, hydroxypropyl methylcellulose K15M, the hydroxypropyl methylcellulose K100M.
4. according to the described carprofen matrix tablet of claim 1, it is characterized in that described filler is one or more in starch, microcrystalline Cellulose, lactose, amylum pregelatinisatum, Icing Sugar, inorganic salt, the mannitol.
5. according to the described carprofen matrix tablet of claim 1, it is characterized in that described lubricant is one or more in magnesium stearate, micropowder silica gel (Aerosil 200 and Aerosil 300), Pulvis Talci, the Polyethylene Glycol.
6. according to the preparation method of the described carprofen matrix tablet of claim 1, it is characterized in that step is as follows:
Principal agent and adjuvant hydroxypropyl methylcellulose, filler, lubricant are crossed 100 mesh sieves, take by weighing recipe quantity principal agent carprofen and filler and minor amounts of lubricants, mix homogeneously adds adhesive system soft material, the granulation of sieving, drying, granulate adds the lubricant of surplus, mixing is pressed into controlled release tablet, promptly.
7. according to the preparation method of the described carprofen matrix tablet of claim 6, it is characterized in that in described adhesive is water, percent by volume are the ethanol water of 5%-30%, starch slurry that mass percent is 1%-15%, mass percentage concentration is 1%-15% a cellulose derivative aqueous solution, mass percentage concentration is 1%-15% polyvidone aqueous solution, aqueous gelatin solution that mass percentage concentration is 1%-15%, the Polyethylene Glycol aqueous solution that mass percentage concentration is 1%-15% any.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910255664 CN102100679A (en) | 2009-12-16 | 2009-12-16 | Carprofen matrix tablets |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910255664 CN102100679A (en) | 2009-12-16 | 2009-12-16 | Carprofen matrix tablets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102100679A true CN102100679A (en) | 2011-06-22 |
Family
ID=44153879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910255664 Pending CN102100679A (en) | 2009-12-16 | 2009-12-16 | Carprofen matrix tablets |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102100679A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104983705A (en) * | 2015-06-04 | 2015-10-21 | 湖北生物医药产业技术研究院有限公司 | Sodium prasterone sulfate sustained-release tablet and preparation method thereof |
| CN110169951A (en) * | 2019-05-17 | 2019-08-27 | 河北远征药业有限公司 | A kind of Carprofen injection for animals and its preparation method and application |
| CN113384543A (en) * | 2021-07-06 | 2021-09-14 | 北京宇和金兴生物医药有限公司 | Carprofen chewable tablet preparation and preparation process method thereof |
-
2009
- 2009-12-16 CN CN 200910255664 patent/CN102100679A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104983705A (en) * | 2015-06-04 | 2015-10-21 | 湖北生物医药产业技术研究院有限公司 | Sodium prasterone sulfate sustained-release tablet and preparation method thereof |
| CN110169951A (en) * | 2019-05-17 | 2019-08-27 | 河北远征药业有限公司 | A kind of Carprofen injection for animals and its preparation method and application |
| CN113384543A (en) * | 2021-07-06 | 2021-09-14 | 北京宇和金兴生物医药有限公司 | Carprofen chewable tablet preparation and preparation process method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10507185B2 (en) | Composite structural material and pharmaceutical composition thereof | |
| EP2037887B1 (en) | Oral controlled release formulations of an interleukin-1 beta converting enzyme inhibitor | |
| WO2006022996A2 (en) | Dosage form containing multiple drugs | |
| CN101431992A (en) | Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof | |
| EP2448561A1 (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application | |
| CN102307575B (en) | Aceclofenac-containing controlled-release oral drug preparations and their manufacturing process | |
| US20110201633A1 (en) | Alfuzosin tablets and synthesis | |
| CN102917696A (en) | Aceclofenac slow-release preparation providing an optimum pharmacological clinical effect when administered once a day | |
| US20050163839A1 (en) | Oral controlled release pharmaceutical composition containing metaxalone as active agent | |
| Patel et al. | Development and evaluation of mucoadhesive vaginal tablet of sertaconazole for vaginal candidiasis | |
| US20060062846A1 (en) | Alfuzosin tablets and synthesis | |
| CN101069686A (en) | Laevo-ornidazole vagina administration preparation, its preparing method and use | |
| CN102100679A (en) | Carprofen matrix tablets | |
| CN103610658A (en) | Immunomodulator slow-release preparation and preparation method thereof | |
| KR20010072269A (en) | Pharmaceutical compositions comprising ibuprofen and domperidone | |
| PL236001B1 (en) | Complex pharmaceutical composition comprising candesartan cilexetil and amlodipine, its preparation method and the unit dosage form comprising said composition, | |
| CN101732235B (en) | Method for preparing solid dispersion of tamoxifen citrate | |
| CN102824644B (en) | High-stability sustained-release tablet prepared by using hydroxy propyl cellulose | |
| CN102008469A (en) | Method for preparing telmisartan amlodipine tablets | |
| KR101076648B1 (en) | Controlled-release Aceclofenac Containing Oral Drug Preparations and it's Manufacturing Process | |
| JP5669751B2 (en) | Pre-compressible formulations of compounds with low oral bioavailability | |
| TW201201800A (en) | A pharmaceutical controlled release composition of losartan | |
| RU2007147953A (en) | PHARMACEUTICAL RECIPES OF MICRONIZED (4-CHLOROPHENYL) [4- (4-pyridylmethyl) -phthalazin-1-yl] AND ITS SALTS WITH IMMEDIATE EXCESSION AND HIGH CONTENT | |
| CN102600094A (en) | Bosentan sustained-release matrix tablet and preparation method thereof | |
| CN101780054A (en) | Compound sustained-release preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110622 |